-
Je něco špatně v tomto záznamu ?
„Qality by design“ – plánované řízení kvality ve farmaceutickém průmyslu
[Quality by design – planned quality management in pharmaceutical industry]
Michal Beneš
Jazyk čeština Země Česko
Typ dokumentu přehledy
- Klíčová slova
- optimalizace, Quality by design,
- MeSH
- farmaceutický průmysl * metody organizace a řízení MeSH
- hodnocení rizik MeSH
- kontrola léčiv a omamných látek * organizace a řízení MeSH
- příprava léků * MeSH
- řízení kvality MeSH
- směrnice jako téma MeSH
- statistika jako téma MeSH
- Publikační typ
- přehledy MeSH
Quality by design is a systematic approach to drug product development and manufacturing that starts by defining the target product quality. It continues with an assessment of the risks to product quality that are involved in the characteristics of the raw materials and in the parameters of the manufacturing process. At the following stage, the actual impact of the characteristics and parameters identified is found through experiments and the design space is defined on that basis. Design space is an abstract multidimensional space in which the desired product quality can be attained by changing and controlling the variables. Based on the advanced knowledge of the product and the process obtained, the process can be optimized effectively and an appropriate control strategy set at points representing the greatest risk to quality or at points where information can be obtained well enough in advance to allow for reversing (by an appropriate adjustment of the process conditions) a potentially inappropriate course of the process. The information gained through the use of quality-by-design tools can then be used to accelerate the registration process of a new drug product and, in particular, for a substantial increase of manufacturing process efficiency and of the certainty that the desired product quality will be achieved.
Quality by design – planned quality management in pharmaceutical industry
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17033755
- 003
- CZ-PrNML
- 005
- 20180611125114.0
- 007
- ta
- 008
- 171128s2017 xr a f 000 0|cze||
- 009
- AR
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Beneš, Michal $7 _AN093830 $u Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, Katedra farmaceutické technologie, Heyrovského 1203, 500 05 Hradec Králové
- 245 10
- $a „Qality by design“ – plánované řízení kvality ve farmaceutickém průmyslu / $c Michal Beneš
- 246 31
- $a Quality by design – planned quality management in pharmaceutical industry
- 504 __
- $a Literatura
- 520 9_
- $a Quality by design is a systematic approach to drug product development and manufacturing that starts by defining the target product quality. It continues with an assessment of the risks to product quality that are involved in the characteristics of the raw materials and in the parameters of the manufacturing process. At the following stage, the actual impact of the characteristics and parameters identified is found through experiments and the design space is defined on that basis. Design space is an abstract multidimensional space in which the desired product quality can be attained by changing and controlling the variables. Based on the advanced knowledge of the product and the process obtained, the process can be optimized effectively and an appropriate control strategy set at points representing the greatest risk to quality or at points where information can be obtained well enough in advance to allow for reversing (by an appropriate adjustment of the process conditions) a potentially inappropriate course of the process. The information gained through the use of quality-by-design tools can then be used to accelerate the registration process of a new drug product and, in particular, for a substantial increase of manufacturing process efficiency and of the certainty that the desired product quality will be achieved.
- 650 12
- $a farmaceutický průmysl $x metody $x organizace a řízení $7 D004345
- 650 _2
- $a směrnice jako téma $7 D017408
- 650 12
- $a kontrola léčiv a omamných látek $x organizace a řízení $7 D004335
- 650 12
- $a příprava léků $7 D004339
- 650 _2
- $a řízení kvality $7 D011786
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a statistika jako téma $7 D013223
- 653 00
- $a optimalizace
- 653 00
- $a Quality by design
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $t Chemické listy $x 0009-2770 $g Roč. 111, č. 9 (2017), s. 559-566 $w MED00011010
- 856 41
- $u http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/41/41 $y domovská stránka časopisu
- 910 __
- $a ABA008 $b B 1918 $c 395 $y 4 $z 0
- 990 __
- $a 20171127085132 $b ABA008
- 991 __
- $a 20180611125326 $b ABA008
- 999 __
- $a ok $b bmc $g 1260674 $s 994810
- BAS __
- $a 3
- BMC __
- $a 2017 $b 111 $c 9 $d 559-566 $i 0009-2770 $m Chemické listy $n Chem. Listy $x MED00011010
- LZP __
- $c NLK185 $d 20180611 $a NLK 2017-49/vt